Lupin receives FDA all-clear for Mandideep API manufacturing facility
Company becomes the fourth Indian pharma firm to secure FDA clearance in the last two weeks
Lupin has become the latest Indian pharmaceutical company to receive a clean bill of health from the US Food and Drug Administration for an active pharmaceutical ingredients (API) manufacturing facility.
On Wednesday, Lupin said it received an Establishment Inspection Report for its Mandideep Unit II plant from the US drug regulator with a Voluntary Action Indicated classification. The inspection at the facility was carried out between November 26, 2018 and December 4, 2018.
A VAI inspection classification indicates that the FDA will not take or recommend regulatory or enforcement action because any objectionable conditions found were not serious enough for it to do so.
“We are pleased to have received the EIR for our Mandideep Unit II facility, our important cardiovascular API manufacturing facility,” said Nilesh Gupta, Managing Director, Lupin. “We remain committed to enhancing compliance and quality standards across all our manufacturing sites.”
Earlier this week, Lupin received another EIR from the FDA for its largest and most-advanced oral solid dosage facility at Nagpur for an inspection carried out between January 6 and January 10, 2020.
Three other Indian companies have been given the FDA all-clear after API facility inspections over the last few days.
Dr. Reddy’s Laboratories received an EIR for its Plant-5 in Miryalaguda of Nalgonda District in Telangana, as did Strides Pharma for its Bengaluru plant. Meanwhile Biocon’s plant in Malaysia which manufactures insulin was also cleared by the FDA.
The robustness of international pharmaceutical supply chains has come into sharp focus recently – particularly from key API producers such as India and China -- as the COVID-19 pandemic continues to spread around the world.
Last week, India relaxed an export ban on anti-malarial drug hydroxychloroquine just 24 hours after US President Donald Trump warned of “retaliation” if the measure was not lifted. However, it is understood that Indian exports of the drug -- which has shown promise in treating patients with COVID-19, but is not currently approved as a therapy for the disease -- will only be made available to foreign governments and not private companies.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance